CLL2-GiVe trial: ibrutinib, venetoclax and obinutuzumab in patients with TP53-mutated CLL

CLL2-GiVe trial: ibrutinib, venetoclax and obinutuzumab in patients with TP53-mutated CLL

Obinutuzumab, ibrutinib, and venetoclax in high-risk CLL: the CLL2-GIVe and CLL13 trialsПодробнее

Obinutuzumab, ibrutinib, and venetoclax in high-risk CLL: the CLL2-GIVe and CLL13 trials

Outcomes in high-risk CLL patients following fixed-duration treatment with ibrutinib plus venetoclaxПодробнее

Outcomes in high-risk CLL patients following fixed-duration treatment with ibrutinib plus venetoclax

ASH CLL highlights: ibrutinib-venetoclax combination & undetectable MRD in IGHV-mutated patientsПодробнее

ASH CLL highlights: ibrutinib-venetoclax combination & undetectable MRD in IGHV-mutated patients

CLL2-GIVe trial: investigating chemotherapy-free treatment of CLLПодробнее

CLL2-GIVe trial: investigating chemotherapy-free treatment of CLL

GLOW: Assessing ibrutinib plus venetoclax in CLLПодробнее

GLOW: Assessing ibrutinib plus venetoclax in CLL

Obinutuzumab, Ibrutinib, & Venetoclax in 17p / TP53 CLL - Dr. Stephan Stilgenbauer ASH 2022Подробнее

Obinutuzumab, Ibrutinib, & Venetoclax in 17p / TP53 CLL - Dr. Stephan Stilgenbauer ASH 2022

MAJIC: Venetoclax with acalabrutinib or obinutuzumab in CLLПодробнее

MAJIC: Venetoclax with acalabrutinib or obinutuzumab in CLL

The SYMPATICO trial: ibrutinib plus venetoclax in TP53-mutated MCLПодробнее

The SYMPATICO trial: ibrutinib plus venetoclax in TP53-mutated MCL

Testing for IgHV and TP53 mutations to guide treatment decisions in CLLПодробнее

Testing for IgHV and TP53 mutations to guide treatment decisions in CLL

The prognostic impact of TP53 and IgHV status in the era of targeted therapies in CLLПодробнее

The prognostic impact of TP53 and IgHV status in the era of targeted therapies in CLL

Triple combination therapy in CLLПодробнее

Triple combination therapy in CLL

iFCG proves promising for IGHV-mutated CLLПодробнее

iFCG proves promising for IGHV-mutated CLL

Updates from the CLL14 and CLL2-GiVe trials on CLLПодробнее

Updates from the CLL14 and CLL2-GiVe trials on CLL

Ibrutinib Plus Venetoclax as a Treatment Option for CLLПодробнее

Ibrutinib Plus Venetoclax as a Treatment Option for CLL

CLL14 trial: do certain patients benefit more from venetoclax plus obinutuzumab in CLL?Подробнее

CLL14 trial: do certain patients benefit more from venetoclax plus obinutuzumab in CLL?

CAPTIVATE: Ibrutinib and venetoclax in CLLПодробнее

CAPTIVATE: Ibrutinib and venetoclax in CLL

Achieving undetectable MRD with ibrutinib plus venetoclax for CLLПодробнее

Achieving undetectable MRD with ibrutinib plus venetoclax for CLL

Overview of the CLL2-BIG trial of ibrutinib and obinutuzumabПодробнее

Overview of the CLL2-BIG trial of ibrutinib and obinutuzumab

Ibrutinib + Venetoclax for CLLПодробнее

Ibrutinib + Venetoclax for CLL

Acalabrutinib, venetoclax and obinutuzumab in previously untreated patients with CLLПодробнее

Acalabrutinib, venetoclax and obinutuzumab in previously untreated patients with CLL